Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Eli Lilly announced agreements to buy Curevo, LimmaTech Biologics, and Vaccine Company, assembling a pipeline focused on shingles, bacterial pathogens, and Epstein-Barr virus using multiple vaccine platforms.
THE APEX TIMES
THE APEX TIMES
Eli Lilly says its once-daily oral GLP-1 orforglipron, marketed as Foundayo, delivered larger A1C reductions in three pivotal type 2 diabetes trials, with weight-loss results emphasized most clearly in a head-to-head study against oral semaglutide.
THE APEX TIMES
A Zacks Investment Ideas feature argues the late-spring to fall period could favor health care, highlighting Eli Lilly’s rapid growth momentum and Merck’s pipeline progress and Keytruda franchise strength.
THE APEX TIMES
In a retrospective claims study presented ahead of the ADA’s 2026 meeting, Novo Nordisk reported similar HbA1c results for semaglutide dose escalation versus switching to tirzepatide, with a statistically higher chance of at least 5% weight loss on the higher semaglutide dose.
THE APEX TIMES
At the American Diabetes Association meeting in New Orleans on Monday, Eli Lilly highlighted Phase 3 results for its next-generation obesity pipeline, while Novo Nordisk stressed momentum for its Wegovy pill and presented Phase 3 data for CagriSema. Investors responded to the two sets of announcements in opposite ways.
THE APEX TIMES
The GLP-1 dual-receptor agonist survodutide produced solid weight and liver-fat findings in Phase 3, but a higher-than-placebo rate of treatment discontinuation tied to gastrointestinal side effects drove a sharp market reaction on June 8, 2026.
THE APEX TIMES
Eli Lilly’s latest clinical readouts across tirzepatide, the investigational retatrutide and oral GLP-1 orforglipron helped reinforce a bullish view after the American Diabetes Association meeting in New Orleans.
THE APEX TIMES
A fresh Zacks-linked article resurfaced on June 8, 2026, asking whether Eli Lilly’s (LLY) momentum is investable at current levels. The broader debate now centers on how durable demand will be for its GLP-1 and related therapies, and how quickly next-wave competitors and pricing pressure could erode growth.
THE APEX TIMES
Investors reacted Monday to additional Phase 3 results for retatrutide, Eli Lilly’s investigational triple-hormone obesity drug, including improvements in knee osteoarthritis pain, obstructive sleep apnea and type 2 diabetes markers.
